EUCTR2008-004699-34-ES进行中（未招募）不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II study to Assess the efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients with Cystic Fibrosis.Estudio fase II de distribución aleatoria, doble ciego, controlado con placebo y de grupos paralelos, para evaluar la eficacia de la administración oral durante 28 días de AZD1236 a pacientes adultos con fibrosis quística - CYBER
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of informed consent prior to any study specific procedures
- •2. Be male or post-menopausal/surgically sterile female (total hysterectomy and/or bilateral total ophorectomy) > 18 years old
- •3. Have a clinical diagnosis of cystic fibrosis with an FEV1 =40% of predicted normal
- •4. Be able to comply with induced sputum procedure
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Significant portal hypertension in the opinion of the Investigator
- •2. Any clinically relevant disease or disorder (past or present), which in the opinion of the investigator may either put the patient at risk because of participation in the study, or influence the results of the study, or the patient's ability to participate in the study
- •3. Concomitant diagnosis of significant pulmonary disease other than CF-related lung disease, including symptomatic asthma and allergic bronchopulmonary aspergillosis
- •4. A clinical suspicion of active or latent tuberculosis defined as any of the following: positive tuberculosis test (such as Quantiferon GOLD), and/or suspicion of active or latent tuberculosis on chest X-ray taken within last 12 months, and/or past medical history of tuberculosis
- •5. An acute exacerbation (defined as, an increase in respiratory symptoms requiring hospitalisation and/or a course of oral glucocorticosteroids and/or antibiotics, either prescribed or self administered); or acute respiratory infection (upper or lower) requiring oral steroids or antibiotics in the 4 weeks prior to Visit 2
- •6. Vaccination (killed vaccine) within 1 week before each biomarker sampling (see Table 2). For live vaccine, the limit is 4 weeks before Visit 2. Vaccination is accepted 1 week after last dose (Visit 4)
- •7. Acute respiratory infection with fever in the two weeks prior to Visit 2, or other acute infections requiring treatment with antibiotics, fungicides or anthelmintica in the 4 weeks before Visit 2
- •8. Use of oral corticosteroids in the 8 weeks prior to Visit 2 (use of inhaled corticosteroids is allowed as long as dose remains stable in the 4 weeks before Visit 2)
- •9. Use of antibiotics (systemic or nebuliser) in the 4 weeks prior to Visit 2 (except prophylactic treatment – acceptable if unchanged for 8 weeks prior to Visit 2), macrolides or tetracyclins not allowed
- •10. Treatment with any immunomodulatory agents within 8 weeks prior to Visit 2
- •11. Increased Cardiac Troponin I>Upper Limit of Normal (ULN) at screening (Visit 1)
- •12. Any clinically relevant abnormal finding in physical examination, clinical chemistry, haematology, urinalysis, vital signs or ECG at baseline, which, in the opinion of the investigator, may put the patient at risk because of his/her participation in the study
- •13. Patients with glomerular filtration rate less than 60 mL/min, calculated as creatinine clearance from serum-creatinine according to the Cockcroft and Gault formula: (CLcreatinine (mL/min)=constant x (140-age) x weight (kg)/serum creatinine (µM). Constant being 1.23 for men and 1.04 for women
- •14. Patients with underlying musculoskeletal symptoms of unknown origin and patients with shoulder girdle musculoskeletal symptoms or Dupuytrens contracture symptoms as judged by the investigator
- •15. Suspected or known risk of the patient transmitting HIV, hepatitis B or C via infected blood
- •16. Known to be infected with Burkholderia cepacia
- •17. Scheduled in-patient surgery or hospitalisation during the course of the study
- •18. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
- •19. Previous randomisation of treatment in the present study
- •20. Known or suspected hypersensitivity to study therapy or excipient of the investigational product.
- •21. Participation in another clinical study involving an investigational product within 12 weeks of Visit 1
- •If the patient participates in the genetic part of the s
研究者
相似试验
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by the Respimat Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD)EUCTR2006-001009-27-HUBoehringer Ingelheim Pharma GesmbH3,000
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily compared with Placebo for 24 Weeks in Adult Subjects with Chronic Obstructive Pulmonary Disease (COPD).EUCTR2010-019695-76-EEGlaxoSmithKline Research & Development675
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 52 Weeks in Adult and Adolescent Subjects with Perennial Allergic RhinitisPerennial allergic rhinitisEUCTR2004-000091-14-LTGlaxoSmithKline736
进行中（未招募）
1 期
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by the Respimat Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD).EUCTR2006-001009-27-SKBoehringer Ingelheim Pharma GesmbH3,000
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by the Respimat Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD) - ROSESChronic Obstructive Pulmonary Disease (COPD).EUCTR2006-001009-27-PTBoehringer Ingelheim (UK), Ltd3,000